62069-75-4

Usage

Uses

Used in Biochemistry Research:
Disuccinimidyl tartarate is used as a crosslinking agent for protein crosslinking in biochemistry research. Its amino reactive nature and 6.4 angstroms spacer arm enable the specific and efficient crosslinking of proteins, which is essential for studying protein-protein interactions and understanding the structure and function of proteins.
Used in Drug Development:
Disuccinimidyl tartarate is used as a protein crosslinking agent in drug development. By crosslinking proteins, it can help in the design and development of drugs that target specific protein-protein interactions, potentially leading to the discovery of new therapeutic agents.
Used in Diagnostics:
Disuccinimidyl tartarate is used as a protein crosslinking agent in the development of diagnostic tools. Its ability to crosslink proteins can be utilized in the creation of immunoassays and other diagnostic tests that rely on the detection of specific protein-protein interactions.
Used in Materials Science:
Disuccinimidyl tartarate is used as a crosslinking agent in the development of protein-based materials. Its ability to crosslink proteins can be employed to create materials with specific properties, such as improved stability or biocompatibility, for various applications in materials science.

Upstream product

• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 87-69-4 tartaric acid 

Relevant academic research and scientific papers

DLL3-TARGETING MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND USES THEREOF

The disclosure provides multispecific antigen-binding molecules that comprise a first antigen-binding moiety and a second antigen-binding moiety, each of which is capable of binding to CD3 and CD137, but does not bind to CD3 and CD137 at the same time; and a third antigen-binding moiety that is capable of binding to DLL3, preferably human DLL3, which induce T-cell dependent cytotoxity more efficiently whilst circumventing adverse toxicity concerns or side effects that other multispecific antigen-binding molecules may have. The present invention provides multispecific antigen-binding molecules and pharmaceutical compositions that can treat various cancers, especially those associated with DLL3, by comprising the antigen-binding molecule as an active ingredient.

NON-HUMAN ANIMAL HAVING HUMAN CD3 GENE SUBSTITUTED FOR ENDOGENOUS CD3 GENE

The present invention provides genetically modified non-human animals which are deficient in at least one or more types of CD3 genes selected from the group consisting of endogenous CD3ε, CD3δ, and CD3γ in its genome and functionally express at least one or more types of human CD3 genes selected from the group consisting of human CD3?, CD3δ, and CD3γ. In the genetically modified non-human animals of the present invention, mature T cell differentiation and production can take place, and immunocompetent cells including T cells can exert their functions. The genetically modified non-human animals of the present invention enable efficient evaluation and screening in the development of therapeutic agents and therapeutic methods that use human CD3-mediated targeted drugs.

Water dispersible pH-responsive chitosan nanogels modified with biocompatible crosslinking-agents

Chitosan nanoparticles were obtained by crosslinking with two biocompatible dicarboxylic acids: polyethylene glycol dicarboxylic acid and tartaric acid. The water-in-oil (W/O) microemulsion method yielded particle sizes around 10-15 nm in the dried state (TEM) and 200-700 nm in the swollen state (QELS) from commercial chitosan. All the synthesized nanogels showed improved water solubility and most of them were stable at physiological pH. QELS studies revealed the influence of the hydrophilic character and flexibility of the crosslinker on the swelling behaviour of the nanogels. The nanoparticles showed a pH-sensitive volume transition that was consistent with the pKa of chitosan. The collected zeta potential data corroborated the electrostatic repulsion mechanism responsible for the pH-responsive behaviour.

COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS

The present disclosure is directed to corn- pounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator-activated receptor (PPAR) gamma agonist-induced fluid retention. The present disclosure is also directed to compounds and methods for the treatment of hypertension. The present disclosure is also directed to compounds and methods for the treatment of gastrointestinal tract disorders, including the treatment or reduction of pain associated with gastrointestinal tract disorders. The methods generally comprise administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that is designed to be substantially active in the gastrointestinal (GI) tract to inhibit NHE-mediated antiport of sodium ions and hydrogen ions therein. More particularly, the method comprises administering to a mammal in need thereof a pharmaceutically effective amount of a compound, or a pharmaceutical composition comprising such a compound, that inhibits NHE-3, -2 and/ or -8 mediated antiport of sodium and/or hydrogen ions in the GI tract and is designed to be substantially impermeable to the layer of epithelial cells, or more specifically the epithelium of the GI tract. As a result of the compound being substantially impermeable, it is not absorbed and is thus essentially systemically non-bioavailable, so as to limit the exposure of other internal organs (e.g., liver, heart, brain, etc.) thereto. The present disclosure is still further directed to a method wherein a mammal is administered such a compound with a fluid-absorbing polymer, such that the combination acts as described above and further provides the ability to sequester fluid and/or salt present in the GI tract